Biocon
Biocon Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.
From Biocon's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28.
- Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27.
- U.S. biosimilar business to gain momentum with launches like aflibercept (Yesafili) expected in H2 FY '27.
- Generics business to scale up with improvements in profitability driven by higher volume and operating leverage; pipeline includes several upcoming launches.
- Operating leverage to improve as capacity utilization rises in both biosimilars and generics.
- Overall volume growth is steady, with a strong focus on sustainable and profitable expansion across all geographies.
- Margins expected to improve with increased scale and better supply chain efficiencies.
- Long-term expectation is balanced growth across North America, Europe, and emerging markets, maintaining roughly 40%, 35%, and 25% mix respectively.
Profitability & Margins
See what Biocon said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete. (Page 5)
- The Malaysia facility capacity is being doubled for both drug substance and drug product, with drug product line qualification happening currently and drug substance doubling by end of FY '26. (Pages 15-16)
- Minor debottlenecking at Bangalore may occur but no large greenfield capex is planned for FY '27 or FY '28. (Page 15)
- Future capital allocation focus will be on profitable and sustainable growth, not large new expansions. (Page 19)
- Operating leverage and margin improvement is expected through better utilization of existing state-of-the-art facilities. (Pages 16 and 19)
- No further major capex beyond Malaysia plant is planned; investments in product development continue. (Page 11 and 19)
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Biocon said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Biocon — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Biocon Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Biocon Q4 FY26 results?
Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.
What is Biocon share price analysis?
Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biocon planning capital expenditure?
The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete.
Keep Biocon on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.